Status:
UNKNOWN
Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis
Lead Sponsor:
Fudan University
Conditions:
Pancreatic Cancer Metastatic to Liver
Oligometastasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study is a prospective, single center, single arm, phase II clinical study in patients with liver metastasis after radical resection of pancreatic cancer. The purpose of this study is to evaluate...
Detailed Description
Microwave ablation, as one of the important treatment methods of liver metastases, has the advantages of radical effect, small trauma and rapid recovery.Microwave ablation combined with chemotherapy a...
Eligibility Criteria
Inclusion
- Age: 18 to 75years old, male or female;
- ECOG PS: 0-2 points;
- Patients with pancreatic ductal adenocarcinoma diagnosed by histology or cytology;
- Expected survival time\> 3 months;
- The functions of important organs meet the following requirements;
- The maximum diameter of single lesion ≤ 5cm or the number of multiple lesions ≤ 5 and the maximum diameter ≤ 3cm;
- Measurable lesions that meet RECIST criteria.
- Platelet ≥75×109/L, hemoglobin ≥85g/L，white blood cell ≥ 3.0 × 109 / L;
- Total bilirubin ≤ 1.5 times upper limit of normal value (ULN) ; ALT and AST ≤ 5 times ULN ;
- Albumin ≥ 28g / L;
- Creatinine ≤ 1.5 times ULN, or creatinine clearance rate ≥ 50ml / min;
- Women of childbearing age must undergo a negative pregnancy test (βHCG) before starting treatment. Women and men of childbearing age (sexual relationships with women of childbearing age) must agree to use them effectively during treatment and 3 months after the last dose of treatment Contraceptive measures;
- Signature of patient information and informed consent.
- Patients who did not participate in other clinical trials within 4 weeks before screening; those who failed in other trials but met the requirements of this trial could be enrolled.
Exclusion
- Patients with distant metastasis include but not limited to lung metastasis, bone metastasis and brain metastasis;
- Other serious diseases or conditions, including congestive heart failure (NYHA grade III or IV), unstable angina, myocardial infarction and cerebral infarction in the past 6 months, severe arrhythmia, prolonged QT interval, active HIV infection or HIV disease, mental disorders, drug abuse, etc;
- Women who are pregnant or nursing, or have fertility but refuse to take contraceptive measures;
- During the enrollment period, a serious active infection requiring antibiotic intravenous treatment occurred;
- In addition to cervical carcinoma in situ, basal cell carcinoma and superficial bladder tumor (TA, tis \& T1). Any cancer cured for more than 3 years before enrollment was allowed to be enrolled;
- Patients who cannot follow the trial protocol or cannot cooperate with follow-up;
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04677192
Start Date
January 1 2021
End Date
December 1 2022
Last Update
December 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China